Figure 5.

Adjuvanation of rF1V with CpG improves protection against Y. pestis C12 aerosol challenge. (A) BALB/c mice were vaccinated with either one subcutaneous dose (x 1) or 2 subcutaneous doses (x 2) that were 3 weeks apart, with mock/PBS, 0.1 µg or 0.5 µg of rF1V with or without 5 µg CpG (n=8). At 29 days post vaccination, BALB/c mice were exposed to 4.81x10⁵ aerosolized CFU (approximately 6 LD₅₀ equivalents) of Y. pestis C12. (B) BALB/c mice were vaccinated with 2 subcutaneous doses that were 3 weeks apart (n=10). At 29 days post vaccination, BALB/c mice were exposed to 6.51x10⁵ aerosolized CFU (approximately 8 LD₅₀ equivalents) of Y. pestis C12. (C) BALB/c mice were vaccinated with 2 subcutaneous doses that were 3 weeks apart (n=10). At 43 days post vaccination, BALB/c mice were exposed to 2.25 x10⁵ aerosolized CFU (approximately 3 LD₅₀ equivalents) of Y. pestis C12. Survival was monitored for 21 days post challenge.